PARTNER 2

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients - The New England Journal of Medicine - 2016

Brief Summary:

In patients with symptomatic severe AS who are intermediate-risk surgical candidates (expected periprocedural mortality ~ 4-8%), TAVI was noninferior to surgical AVR with respect to all-cause mortality and disabling stroke at 2 years.

Reference:
http://www.ncbi.nlm.nih.gov/pubmed/27040324